Evidence map›Paper›PMID 34490084›Full record

ReviewFrontiers in oncology2021

Current Insights and Advancements in Head and Neck Cancer: Emerging Biomarkers and Therapeutics with Cues from Single Cell and 3D Model Omics Profiling.

Yashika Jawa, Pooja Yadav, Shruti Gupta, Sivapar V Mathan, Jyoti Pandey, Ajay K Saxena, Suneel Kateriya, Ashu B Tiku, Neelima Mondal, Jaydeep Bhattacharya and 5 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Yashika JawaSpecial Center for Molecular Medicine, Jawaharlal Nehru University, New Delhi, India.
Pooja YadavSpecial Center for Molecular Medicine, Jawaharlal Nehru University, New Delhi, India.
Shruti GuptaSchool of Computational and Integrative Sciences, Jawaharlal Nehru University, New Delhi, India.
Sivapar V MathanSchool of Life Sciences, Jawaharlal Nehru University, New Delhi, India.
Jyoti PandeySchool of Biotechnology, Jawaharlal Nehru University, New Delhi, India.
Ajay K SaxenaSchool of Life Sciences, Jawaharlal Nehru University, New Delhi, India.
Suneel KateriyaSchool of Biotechnology, Jawaharlal Nehru University, New Delhi, India.
Ashu B TikuSchool of Life Sciences, Jawaharlal Nehru University, New Delhi, India.
Neelima MondalSchool of Life Sciences, Jawaharlal Nehru University, New Delhi, India.
Jaydeep BhattacharyaSchool of Biotechnology, Jawaharlal Nehru University, New Delhi, India.
Shandar AhmadSchool of Computational and Integrative Sciences, Jawaharlal Nehru University, New Delhi, India.
Rupesh ChaturvediSchool of Biotechnology, Jawaharlal Nehru University, New Delhi, India.
Rakesh K TyagiSpecial Center for Molecular Medicine, Jawaharlal Nehru University, New Delhi, India.
Vibha TandonSpecial Center for Molecular Medicine, Jawaharlal Nehru University, New Delhi, India.
Rana P SinghSchool of Life Sciences, Jawaharlal Nehru University, New Delhi, India.
Jawaharlal Nehru University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Head and neck cancer (HNC) is among the ten leading malignancies worldwide, with India solely contributing one-third of global oral cancer cases. The current focus of all cutting-edge strategies against this global malignancy are directed towards the heterogeneous tumor microenvironment that obstructs most treatment blueprints. Subsequent to the portrayal of established information, the review details the application of single cell technology, organoids and spheroid technology in relevance to head and neck cancer and the tumor microenvironment acknowledging the resistance pattern of the heterogeneous cell population in HNC. Bioinformatic tools are used for study of differentially expressed genes and further omics data analysis. However, these tools have several challenges and limitations when analyzing single-cell gene expression data that are discussed briefly. The review further examines the omics of HNC, through comprehensive analyses of genomics, transcriptomics, proteomics, metabolomics, and epigenomics profiles. Patterns of alterations vary between patients, thus heterogeneity and molecular alterations between patients have driven the clinical significance of molecular targeted therapies. The analyses of potential molecular targets in HNC are discussed with connotation to the alteration of key pathways in HNC followed by a comprehensive study of protein kinases as novel drug targets including its ATPase and additional binding pockets, non-catalytic domains and single residues. We herein review, the therapeutic agents targeting the potential biomarkers in light of new molecular targeted therapies. In the final analysis, this review suggests that the development of improved target-specific personalized therapies can combat HNC's global plight.

Indexed as

3D culturehead and neck (H&N) canceromics analysesorganoid technologysingle cell analysis (SCA)therapeutics of HNC

Identifiers

PMID34490084
PMCPMC8418074
OpenAlexW3193702514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.